Cargando…
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
SIMPLE SUMMARY: Prostate cancer still represents an important health problem in men, considering its high frequency. Over the last decade, novel treatment options have emerged, leading to notable clinical benefits. These recent scientific acquisitions are creating the basis to widen the treatment sc...
Autores principales: | Marchetti, Andrea, Rosellini, Matteo, Nuvola, Giacomo, Tassinari, Elisa, Mollica, Veronica, Rizzo, Alessandro, Santoni, Matteo, Cimadamore, Alessia, Farolfi, Andrea, Montironi, Rodolfo, Fanti, Stefano, Massari, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869833/ https://www.ncbi.nlm.nih.gov/pubmed/35205654 http://dx.doi.org/10.3390/cancers14040907 |
Ejemplares similares
-
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
por: Marchetti, Andrea, et al.
Publicado: (2021) -
An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
por: Mollica, Veronica, et al.
Publicado: (2021) -
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022) -
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
por: Mollica, Veronica, et al.
Publicado: (2022) -
Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review
por: Cimadamore, Alessia, et al.
Publicado: (2021)